PDF(Pubmed)
Abstract：
UNASSIGNED: The present study was to investigate three different single-drug regimens to show which was more effective to reduce radioactive iodine therapy (RAI) associated nausea and vomiting, and to compare the occurrence of long-term gastrointestinal diseases after RAI therapy.
UNASSIGNED: We performed a single-center, non-randomized clinical trial among patients who underwent RAI therapy from March 2016 to July 2022. Enrolled patients were divided into four cohorts based on the date of the treatment. cohort 1, with no preventive antiemetics; cohort 2, received 20 mg of pantoprazole per day for 3 days; cohort 3, received a 10 mg metoclopramide tablet two times daily for 3 days; cohort 4, oral ondansetron, 8 mg, twice daily for 3 days. The primary endpoints were proportion of patients who experience vomiting episodes and nausea during the 7-day hospital period. Secondary end points included Functional Living Index Emesis (FLIE) quality-of life questionnaires and the occurrence of gastrointestinal diseases.
UNASSIGNED: A total of 1755 patients were analyzed, comprised of 1299 (74.0%) women and 456 (26.0%) men, with a median age of 44 years (range 18-78 years). The characteristics of patient were similar within the four groups. 465 (26.4%) patients developed RAI-associated nausea, and 186 (14.4%) patients developed RAI-associated vomiting. The rate of nausea was significantly decreased in the patients who were taking ondansetron when compared with the other cohorts (P<0.05), while the rate of vomiting (≥6 episodes) was slightly lower. As secondary endpoint, FLIE measures ondansetron scored highly compared to other cohorts, from baseline (mean score of 110.53 ± 17.54) to day 7 (mean score of 105.56 ± 12.48). In addition, 48 (2.7%) patients were found to be with gastrointestinal diseases at the end of one year follow up. Multiple RAI therapy and higher dose of I-131 per body weight revealed a significantly independent risk factors of developing gastrointestinal disorders.
UNASSIGNED: In conclusion, the present study demonstrated that short-term ondansetron could be an effective prophylactic agent in controlling RAI-associated nausea and vomiting. Furthermore, the risk of developing gastrointestinal disorders was significantly higher for patients with multiple RAI therapy and higher dose of I-131 per body weight.
UNASSIGNED: We performed a single-center, non-randomized clinical trial among patients who underwent RAI therapy from March 2016 to July 2022. Enrolled patients were divided into four cohorts based on the date of the treatment. cohort 1, with no preventive antiemetics; cohort 2, received 20 mg of pantoprazole per day for 3 days; cohort 3, received a 10 mg metoclopramide tablet two times daily for 3 days; cohort 4, oral ondansetron, 8 mg, twice daily for 3 days. The primary endpoints were proportion of patients who experience vomiting episodes and nausea during the 7-day hospital period. Secondary end points included Functional Living Index Emesis (FLIE) quality-of life questionnaires and the occurrence of gastrointestinal diseases.
UNASSIGNED: A total of 1755 patients were analyzed, comprised of 1299 (74.0%) women and 456 (26.0%) men, with a median age of 44 years (range 18-78 years). The characteristics of patient were similar within the four groups. 465 (26.4%) patients developed RAI-associated nausea, and 186 (14.4%) patients developed RAI-associated vomiting. The rate of nausea was significantly decreased in the patients who were taking ondansetron when compared with the other cohorts (P<0.05), while the rate of vomiting (≥6 episodes) was slightly lower. As secondary endpoint, FLIE measures ondansetron scored highly compared to other cohorts, from baseline (mean score of 110.53 ± 17.54) to day 7 (mean score of 105.56 ± 12.48). In addition, 48 (2.7%) patients were found to be with gastrointestinal diseases at the end of one year follow up. Multiple RAI therapy and higher dose of I-131 per body weight revealed a significantly independent risk factors of developing gastrointestinal disorders.
UNASSIGNED: In conclusion, the present study demonstrated that short-term ondansetron could be an effective prophylactic agent in controlling RAI-associated nausea and vomiting. Furthermore, the risk of developing gastrointestinal disorders was significantly higher for patients with multiple RAI therapy and higher dose of I-131 per body weight.
摘要：
■本研究是调查三种不同的单一药物治疗方案，以表明哪种方案更有效地减少放射性碘治疗（RAI）相关的恶心和呕吐，并比较RAI治疗后长期胃肠道疾病的发生情况。
■我们执行了单中心，2016年3月至2022年7月接受RAI治疗的患者的非随机临床试验.根据治疗日期，将纳入的患者分为四个队列。队列1，没有预防性止吐药；队列2，每天接受20毫克泮托拉唑，持续3天；队列3，每天两次接受10毫克甲氧氯普胺片剂，持续3天；队列4，口服昂丹司琼，8毫克，每天两次，持续3天。主要终点是在7天住院期间经历呕吐发作和恶心的患者比例。次要终点包括功能生活指数呕吐（FLIE）生活质量问卷和胃肠道疾病的发生。
■共分析了1755例患者，由1299名(74.0%)女性和456名(26.0%)男性组成，年龄中位数为44岁（范围18-78岁）。四组患者的特征相似。465例（26.4%）患者出现RAI相关性恶心，186例(14.4%)患者出现RAI相关性呕吐.与其他队列相比，服用昂丹司琼的患者的恶心发生率显着降低（P<0.05），而呕吐（≥6次）的发生率略低。作为次要端点，与其他队列相比，FLIE措施昂丹司琼得分很高，从基线（平均得分为110.53±17.54）到第7天（平均得分为105.56±12.48）。此外,在一年的随访结束时，发现48例（2.7％）患者患有胃肠道疾病。多次RAI治疗和每体重较高剂量的I-131揭示了发生胃肠道疾病的显着独立危险因素。
■总而言之，本研究表明,短期服用昂丹司琼可能是一种有效的预防RAI相关恶心和呕吐的药物.此外，对于接受多次RAI治疗和高剂量I-131/体重治疗的患者,发生胃肠道疾病的风险显著较高.
■我们执行了单中心，2016年3月至2022年7月接受RAI治疗的患者的非随机临床试验.根据治疗日期，将纳入的患者分为四个队列。队列1，没有预防性止吐药；队列2，每天接受20毫克泮托拉唑，持续3天；队列3，每天两次接受10毫克甲氧氯普胺片剂，持续3天；队列4，口服昂丹司琼，8毫克，每天两次，持续3天。主要终点是在7天住院期间经历呕吐发作和恶心的患者比例。次要终点包括功能生活指数呕吐（FLIE）生活质量问卷和胃肠道疾病的发生。
■共分析了1755例患者，由1299名(74.0%)女性和456名(26.0%)男性组成，年龄中位数为44岁（范围18-78岁）。四组患者的特征相似。465例（26.4%）患者出现RAI相关性恶心，186例(14.4%)患者出现RAI相关性呕吐.与其他队列相比，服用昂丹司琼的患者的恶心发生率显着降低（P<0.05），而呕吐（≥6次）的发生率略低。作为次要端点，与其他队列相比，FLIE措施昂丹司琼得分很高，从基线（平均得分为110.53±17.54）到第7天（平均得分为105.56±12.48）。此外,在一年的随访结束时，发现48例（2.7％）患者患有胃肠道疾病。多次RAI治疗和每体重较高剂量的I-131揭示了发生胃肠道疾病的显着独立危险因素。
■总而言之，本研究表明,短期服用昂丹司琼可能是一种有效的预防RAI相关恶心和呕吐的药物.此外，对于接受多次RAI治疗和高剂量I-131/体重治疗的患者,发生胃肠道疾病的风险显著较高.
